Vaccine study to lower HPV spread in HPV-positive women
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older, and you can join through a routine cervical or gynecologic visit
- Your HPV test shows HPV16 and/or HPV18 (or double-positive), and your other high-risk HPV types are negative
- You were recently told you have HPV16/18 (within the last 10 months)
- You fit one of these situations: no visible cervix lesion, mild/moderate cervix lesion (CIN1/2) that can be watched, certain HPV-related anal situations, or certain HPV-related vulvar problems
- You do not need a procedure for a cervix lesion that would affect the cervix within the next 7 months
- You are not pregnant and do not plan to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
This study looks at the safety and immune response of a 9-valent HPV vaccine. It is for women who have already received a full course of certain HPV vaccines and are now getting a different one to see if it boosts their immunity.
This study tests whether a single dose of the HPV vaccine is enough to protect against the viruses that cause several cancers. You will have the vaccine and some small tissue samples taken to see how your immune system responds.
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
This trial tests whether a vaccine against HPV can help prevent pre-cancerous lesions from coming back after you've had them. It's for people who have had high-grade pre-cancerous lesions but haven't yet been treated for them.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
Hear when a new Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.